Glioblastoma Foundation Expands Trial to Study Osimertinib

Glioblastoma Foundation has added a new trial site to expand the Osimertinib trial. Dr. Stephen Bagley at the University of Pennsylvania will be recruiting EGFRvIII+ patients newly diagnosed with glioblastoma to study Osimertinib’s effectiveness as a potential therapy for patients with EGFRvIII+ glioblastoma. The study will be completed over the next 18 months. The Glioblastoma Foundation is committed to bringing Osimertinib to market as a therapy for glioblastoma patients, if found to be effective.

Osimertinib is currently marketed by AstraZeneca to treat Non-Small Cell Lung Cancer and metastasis and has been shown to be effective at treating associated metastasis to the brain.

We look forward to working with AstraZeneca to make Osimertinib available as a therapy for glioblastoma patients, and call on the company to make the drug widely available for glioblastoma patients should it be shown to be effective at treating the disease.

Dr. Bagley shares our passion for bringing Osimertinib to glioblastoma patients and we are excited to work with his team on this trial!

The current standard of care for glioblastoma consisting of radiation and chemotherapy is ineffective.

Help Us Transform Glioblastoma Therapy